ADVM241220P6000
- 0.65
- 0.000.00%
Adverum Biotechnologies Newsroom
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Cuts Target Price to $16
Adverum Biotechnologies Price Target Lowered to $16 From $20 at Mizuho
Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
H.C. Wainwright Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $30
Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials
Buy Rating on Adverum Biotechnologies: Ixo-vec's Promising Potential in Transforming Wet AMD Treatment
Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
Express News | Adverum Biotechnologies Inc: 6E10 Dose in Luna Maintains Visual and Anatomic Endpoints
Express News | Adverum Biotechnologies Inc: Expects to Be Able to Fund Operations Into Second Half of 2025
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Adverum Biotechnologies Analyst Ratings
RBC Capital Initiates Adverum Biotechnologies(ADVM.US) With Hold Rating, Announces Target Price $10
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Adverum Biotechnologies Price Target Lowered to $10 From $12 at RBC Capital
A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $10 to $30
Buy Rating on Adverum Biotechnologies Driven by Ixo-vec's Promising Data and Potential Impact on AMD Treatment